Hisamitsu Pharmaceutical Co. (OTCPK:HTSUF) subsidiary Noven Pharmaceuticals announces the FDA nod for SECUADO (asenapine) transdermal patch for the treatment of adults with schizophrenia.
Market launch will commence shortly.
Asenapine is marketed in the U.S. as a sublingual tablet under the brand name Saphris by Allergan (NYSE:AGN) under a license from Merck (NYSE:MRK).
https://seekingalpha.com/news/3505759-fda-oks-hisamitsu-pharmas-asenapine-patch-schizophrenia
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.